Cyteir Therapeutics

📍 Lexington, United States🗓 Founded 2012👥 21 employees💰 Last funded Sep 2019
Research Services🌐 cyteir.com
Website LinkedIn
Cyteir is a clinical-stage oncology company that is focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. Cyteir’s current priority in CYT-0851 development is in combination with capecitabine and gemcitabine in a Phase 1/2 clinical study, including patients with advanced ovarian cancer.
3
Total investors
1
Early stage
0
Mid stage
2
Late stage
2012
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
3
Investor activity2012–2019 · investors recorded per year
201212018120191
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Cyteir Therapeutics?
Cyteir Therapeutics has 3 investors on record on gritt.io, including 1 early-stage backers and 2 late-stage investors.
When did Cyteir Therapeutics last raise funding?
The most recent investment in Cyteir Therapeutics recorded on gritt.io was in September 2019.
When was Cyteir Therapeutics founded?
Cyteir Therapeutics was founded in 2012.
What industry is Cyteir Therapeutics in?
Cyteir Therapeutics operates in Research Services. Find similar Research Services investors on gritt.io.
Where is Cyteir Therapeutics based?
Cyteir Therapeutics is headquartered in Lexington, United States.